Last mentioned: Mar 25, 2026
Keytruda Patent Expiration
The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.
Pipeline Integration
Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.
Expected Closing
Anticipated completion of the acquisition following regulatory and shareholder approvals.
Acquisition Announced
Merck and Terns Pharmaceuticals announce a definitive $6.7 billion merger agreement.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares for the impending patent expiration of its top-selling cancer immunotherapy, Keytruda, later this decade.
This page surfaces every story mentioning TERN-701 across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where TERN-701 was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |